Soleno Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Soleno Therapeutics de 66.8% y 77% respectivamente, mientras que el BPA crecerá en un 58.6% al año.

Información clave

66.8%

Tasa de crecimiento de los beneficios

58.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	30.2%
Tasa de crecimiento de los ingresos	77.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BST:6XC1 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2024	37	-18	N/A	N/A	2
12/31/2023	N/A	-32	N/A	N/A	2
12/31/2022	N/A	-28	N/A	N/A	2
6/30/2022	N/A	-23	-23	-23	N/A
3/31/2022	N/A	-28	-27	-27	N/A
12/31/2021	N/A	-31	-28	-28	N/A
9/30/2021	N/A	-31	-28	-28	N/A
6/30/2021	N/A	-31	-29	-29	N/A
3/31/2021	N/A	-28	-27	-27	N/A
12/31/2020	N/A	-25	-25	-25	N/A
9/30/2020	N/A	-36	-23	-23	N/A
6/30/2020	N/A	-27	-22	-22	N/A
3/31/2020	N/A	-30	-19	-19	N/A
12/31/2019	N/A	-31	-17	-17	N/A
9/30/2019	N/A	-16	-16	-16	N/A
6/30/2019	N/A	-19	-14	-14	N/A
3/31/2019	N/A	-16	-13	-13	N/A
12/31/2018	N/A	-12	-12	-12	N/A
9/30/2018	N/A	-16	-11	-11	N/A
6/30/2018	N/A	-17	-10	-10	N/A
3/31/2018	N/A	-13	-10	-10	N/A
12/31/2017	N/A	-12	-10	-10	N/A
9/30/2017	N/A	-13	-10	-10	N/A
6/30/2017	0	-11	-11	-11	N/A
3/31/2017	0	-9	-12	-12	N/A
12/31/2016	N/A	-10	-14	-13	N/A
9/30/2016	0	-8	-14	-14	N/A
6/30/2016	0	-10	-15	-14	N/A
3/31/2016	1	-7	N/A	-12	N/A
12/31/2015	N/A	-10	N/A	-10	N/A
9/30/2015	0	-20	N/A	-8	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 6XC1 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 6XC1 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 6XC1 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que 6XC1 no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que 6XC1 no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 6XC1 se prevé que sea elevada dentro de 3 años.

Soleno Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

New 90-day low: €1.14

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: €1.85

New 90-day high: €1.70

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

New 90-day low: €1.35

Soleno Therapeutics, Inc. Announces the Body Composition Data from the Company’s Phase III trial, DESTINY PWS (C601)

Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors

Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento